| Ytd | -36.02% | |
| 1y | 41.10% |
| Open | 1.81 | Prev Close | 1.77 | Low | 1.78 | High | 2.13 | Mkt Cap | 87.87M |
| Vol | 1.66M | Avg Vol | 856.68K | EPS | -0.58 | P/E | -3.55 | Forward P/E | -1.76 |
| Beta | 0.34 | Short Ratio | 1.65 | Inst. Own | 7.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 1.78 | 200-d Avg | 2.19 | 1yr Est | 7.33 |
GANX News
Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.11) per share which beat the analys
To our valued Shareholders,As we progress through 2026 and look ahead to delivering continued signif
BETHESDA, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) wit
Gainers Gain Therapeutics (NASDAQ:GANX) stock rose 20.2% to $2.38 during Monday's after-market
IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S.,
IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S.,
BETHESDA, Md., June 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or
MDS-UPDRS scores remained stable and durable across overall study population after 150 days of treat
BETHESDA, Md., May 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or t
Gain Therapeutics' lead drug candidate, GT-02287, is in clinical development for the treatment o
BETHESDA, Md., April 24, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or
Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.11) per share which beat the analys
BETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or
Gain Therapeutics (NASDAQ: GANX) is developing oral small-molecule drugs aimed at neurodegenerative
BETHESDA, Md., March 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or
Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage
Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD
Gain Therapeutics, Inc. (NASDAQ: GANX - Get Free Report) shot up 3.7% on Monday. The stock traded as
Interim analysis of Phase 1b clinical study of GT-02287, including biomarker and clinical endpoints,
BETHESDA, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or
BETHESDA, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or
Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage b
BETHESDA, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or
Gain Therapeutics (GANX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism abo
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) wit
BETHESDA, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or
Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage b
Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph)
Does Gain Therapeutics, Inc. (GANX) have what it takes to be a top stock pick for momentum investors
Shares of Gain Therapeutics, Inc. (NASDAQ: GANX - Get Free Report) have received an average rating o
On Tuesday, 540 companies set new 52-week lows.
Upgrades
During Tuesday's trading, 505 companies set new 52-week lows.
During Friday's session, 445 companies made new 52-week lows.
During Tuesday's morning trading, 87 companies set new 52-week lows.